David M. Mintzer But Where is My Doctor? The Increasing and Relentless Fragmentation of Oncology Care , Journal of Clinical Oncology , 41(26): 2023,4313

Mintzer D, Henry D FDA approvals in hematology and oncology, Part II: New oral formulations, RET and MET inhibitors, and CAR T-cell therapies , MDEdge: 2021

Mintzer D, Henry D FDA approvals in hematology and oncology: Novel agents and new tricks for old drugs , MDEdge: 2021

David Mintzer MKSAP 19, Oncology, Sections on lymphoma, melanoma, effects of cancer therapy and survivorship , American College of Physicians: 2021

Deye, DL; Mintzer D MKSAP 19 Audio companion , Oakstone: 2021

Mintzer D MKSAP 19, Oncology, Sections on lymphoma, melanoma, effects of cancer therapy and survivorship , American College of Physicians: 2021

Bryer E, Mintzer D, Henry DH 2019 At a Glance: Hem-Onc U.S. Drug Approvals , MDedge/Hematology and Oncology: 2019

Emily Bryer, Monique Neault, David Mintzer Managing Dying: Medical Care and Decision Making at the Very End-of-Life , Palliative Medicine & Care: Open Access: 2019,DOI: http://dx.doi.org/10.15226/2374-8362/6/1/00180

Bryer E, Mintzer D, Henry D 2018 At A Glance: Recently Approved Therapies in Oncology , MD Edge/Hematology and Oncology : 2019,://mdedge-files-live.s3.us-east-2.amazonaws.com

Deshields TL, Dueck AC, Rogers K, Brown JR, Shanafelt T, Mintzer D, Byrd JC Perceived risk for cancer progression and psychological status in chronic lymphocytic leukemia patients: CALGB 70603 (Alliance). , Leukemia and Lymphoma : 2019,1-4